THE GLOBAL PREMATURE EJACULATION THERAPEUTICS MARKET IS EXPECTED TO REACH USD 4.06 BILLION BY 2029 FROM USD 2.45 BILLION IN 2023, GROWING AT A CAGR OF 8.74% DURING THE FORECAST PERIOD.

The Premature Ejaculation Therapeutics Market Size, Share, & Trends Analysis Report by

  • Drug Class: Selective Serotonin Re-uptake Inhibitors (SSRIs), Phosphodiesterase type 5 (PDE5) Inhibitors, Anesthetic Agents, and Others
  • Route of Administration: Oral Therapeutics and Topical Therapeutics
  • Age Group: Below 45 Years and Above 45 Years
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

109 Pages

icon-table

04 Tables

icon-chart

30 Charts

icon-region

5 Regions

icon-country

16 Countries

icon-company

18 Companies

icon-market

4 Market Segment

PREMATURE EJACULATION THERAPEUTICS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2029) USD 4.06 Billion
Market Size (2023) USD 2.45 Billion
CAGR (2023-2029) 8.74%
STUDY PERIOD 2020-2029
BASE YEAR 2023
Forecast Year 2024-2029
Market Segments Drug Class, Route of Administration, Age Group, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
KEY VENDORS Plethora Solutions, Absorption Pharmaceuticals, Pfizer, Eli Lilly and Company, GSK plc, and Bayer AG

INDUSTRY OUTLOOK

The global premature ejaculation therapeutics market was valued at USD 2.45 billion in 2023 and is expected to reach USD 4.06 billion by 2029, growing at a CAGR of 8.74% during the forecast period. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally. Considering the high prevalence of the disease, vendors, government organizations, and healthcare professionals are focusing on increasing awareness about the disease and trying to widen the reach of PE therapeutics through multiple distribution channels. Moreover, the high prevalence of premature ejaculation is driving many market players to develop innovative drug formulations for the management of premature ejaculation, which is contributing to the premature ejaculation therapeutics market growth. Also, constant product development and advanced drug formulations with minimal side effects are keys to achieving high sales growth. Product diversification plays a vital role in strengthening the market position of key vendors.

WHY THIS REPORT?

This report provides

  • A thorough insight into the structure and size of each industry segment.
  • An Analysis of several micro-market indicators considering growth factors, market prospects, and strategic contribution to the industry.
  • Overviews of top manufacturers/marketed products, pipeline analysis, clinical trial analysis, competitive landscape, vendor profiles, mergers & acquisitions.
  • Provide strategic planning, such as comprehensively understanding consumer behavior, competitors, new product development, geographic market expansion, and merger & acquisition pipelines.
  • Insights to formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing various competitors' performance.
  • Identifies emerging players with potentially strong product portfolios and creates effective counter strategies to gain a competitive advantage.

MARKET TRENDS & DRIVERS

Advancements in PE Drug Formulation Technology
With the application of nanotechnology, researchers have explored new approaches to medicine delivery to promote efficacy and minimize the side effects of the currently available agents for premature ejaculation. Pharmaceutical advancements improve the effectiveness and safety of drugs by enhancing bioavailability, improving drug absorption, and modifying the drug release rate. Drug formulation of PE drugs has experienced advancements in recent years. For instance, PE drugs such as Absorption Pharmaceuticals' Promescent and Plethora Solutions' Fortacin are formulated as topical eutectic liquid sprays. Rapid advancements will drive the premature ejaculation therapeutics market growth during the forecast period.

Wide Accessibility of OTC Drugs and & General Off-label Drugs for PE
Most of the drugs prescribed for treating PE are off-label. The availability of low-cost generics of off-label PE drugs such as sildenafil, tadalafil, and vardenafil and the high accessibility of OTC PE drugs through physical drug stores, specialty health stores, and e-pharmacies are contributing majorly to the increased uptake of therapeutic medicines over other alternative methods for treating PE.

High Demand for Topical Drug Therapies to Treat PE
Topical therapies that are commonly used result in prolonged intravaginal ejaculatory latency time at the expense of potential penile/vaginal hypotheses. A topical lidocaine-prilocaine-containing spray (FORTACIN) has been developed, with initial results demonstrating a 6.3-fold increase in the intravaginal ejaculatory latency time and an associated improvement in patient-reported outcome measures of control and sexual satisfaction. Almost all topical PE drugs are available as OTC drugs that consumers can purchase without a physician’s prescription. Topical drugs are mainly amide anesthetics, which comprise lidocaine, benzocaine, or a combination of lidocaine and prilocaine. They offer improved ease of use and are associated with minimal/no systemic adverse events. Such improved drug therapies are likely to drive the future growth of the global premature ejaculation therapeutics market.

SEGMENTATION INSIGHTS

INSIGHTS BY DRUG CLASS
The global premature ejaculation therapeutics market by drug class is segmented into Selective Serotonin Re-uptake Inhibitors (SSRIs), Phosphodiesterase type 5 (PDE5) Inhibitors, anesthetic agents, and others. The Selective Serotonin Re-uptake Inhibitors (SSRIs) segment accounted for the largest industry share and is anticipated to retain its market dominance during the forecast period. SSRIs are considered effective drugs for treating PE, and they majorly include sertraline, paroxetine, fluoxetine, escitalopram, citalopram, and dapoxetine. Among these, dapoxetine (Priligy) is the only licensed drug for treating PE in New Zealand, Sweden, Austria, Finland, Germany, Spain, Italy, and Portugal. Apart from Priligy, all other SSRIs that are recommended for the treatment of PE are used as off-label medications. Further, through multiple evidence-based clinical studies, the satisfactory efficacy and safety of SSRIs in delaying ejaculation have been demonstrated. Thus, despite the regulatory authority approval, the off-label use of SSRIs in the management of PE is currently recommended by the AUA guidelines, the updated second ISSN guidelines, and many others.

INSIGHTS BY ROUTE OF ADMINISTRATION
The oral PE therapeutics market segment was the major revenue contributor in 2023, as physicians majorly prescribe oral therapeutics for treating PE; the oral PE therapeutics segment is the major revenue contributor to the global premature ejaculation therapeutics market. Although the number of oral medications recommended or used for the treatment of PE is high, all these drugs (except Priligy) are off-label. Oral therapeutics may be administered either daily or on-demand before sexual intercourse. Further, the growing PE prevalent population and increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment of the global premature ejaculation therapeutics market. Generic versions are approved for almost all off-label drugs recommended for the treatment of PE, such as Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro. Also, the availability of low-cost generic drugs has significantly increased the uptake of oral PE drugs for the management of PE in both developed and developing countries.

INSIGHTS BY AGE GROUP
The below 45 Years age group dominated the global premature ejaculation therapeutics market share in 2023. The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the industry growth during the forecast period. Moreover, changes in lifestyles, smoking, and consumption of alcohol are a few significant factors contributing to the rising disease pool.

GEOGRAPHICAL ANALYSIS

North America was the largest geographical segment of the global premature ejaculation therapeutics market in 2022, with a share of over 43%. The presence of a large proportion of the PE population, coupled with better access to PE, especially OTC drugs, is the primary factor for its high industry share. Moreover, the region's disease prevalence will likely increase during the forecast period. The increased stressful lifestyle and rise in chronic conditions like diabetes and prostate cancer can lead to the incidence of PE. Also, an increased incidence of cancers, especially prostate cancer, is likely to contribute to higher PE prevalence during the forecast period.

Further, the U.S. accounted for a significant share of the North American premature ejaculation therapeutics market in 2023. The country holds the highest market value due to better healthcare accessibility, coverage, and spending. The demand for PE treatment in the country is increasing at a healthy rate owing to the significant rise in prevalence/incidence of premature ejaculation in adult men. According to the National Health and Social Life Survey (NHSLS), an estimated 60%-70% of males in the U.S. experience some form of premature ejaculation. The organization estimated that the country has a prevalence rate of 30%, increasing steadily among all the young and adult age groups.

The European region holds a significant share of the global premature ejaculation therapeutics market, is growing at a healthy rate, and is expected to grow at a similar pace during the forecast period. Europe, particularly Western Europe, has a sophisticated and established healthcare infrastructure, and people have access to advanced healthcare services, including treatment for male sexual dysfunction like premature ejaculation. The significant share of the region in the global premature ejaculation therapeutics market is mainly due to the high prevalence of PE disorders, the presence of major and emerging vendors either marketing or distributing PE drugs, and wide access to multiple off-label and OTC PE drug formulations. Further, the prevalence of PE across European countries is likely to rise during the forecast period, which, in turn, is expected to contribute to increasing the PE treatment pool, thereby driving the size of the PE industry. The growing prevalence of diseases that are associated with the risk of PE incidence as a co-morbid condition and the rise in acute and chronic stress will drive the PE prevalence population.

VENDOR LANDSCAPE

The global premature ejaculation therapeutics market is relatively fragmented and characterized by pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors offer off-label drugs, generic versions, and OTC topical anesthetic agents. Drugs offered by global players in the global premature ejaculation therapeutics market, such as Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline, are used as off-label drugs for treating PE. Therefore, these international players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan, are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs for treating PE. In recent years, the global premature ejaculation therapeutics market has witnessed many strategic initiatives by key vendors, intensifying market competitiveness. In 2014, Royalty Pharma acquired the rights of Priligy from Allergan to expand its product portfolio and establish its presence in the premature ejaculation therapeutics market.

Frequently Asked Questions

How big is the premature ejaculation therapeutics market?

The premature ejaculation therapeutics market size was valued at USD 2.45 billion in 2023 and is expected to reach USD 4.06 billion by 2029.

What is the projected growth rate of the global premature ejaculation therapeutics market?

The global premature ejaculation therapeutics market is projected to grow at a CAGR of 8.74% during the forecast period.

What are the rising trends in the premature ejaculation therapeutics market?

The rising trends in the premature ejaculation therapeutics market are advancements in PE drug formulation technology, the presence of high unmet needs, and the high demand for topical drug therapies to treat PE.

Which region holds the most significant global premature ejaculation therapeutics market share?

North America dominated the global premature ejaculation therapeutics market share, accounting for over 43% in 2023.

Who are the key players in the global premature ejaculation therapeutics market?

Plethora Solutions, Absorption Pharmaceuticals, Pfizer, Eli Lilly and Company, GSK plc, and Bayer AG are the key players in the global premature ejaculation therapeutics market.

Download Free Sample

The global premature ejaculation therapeutics market size is expected to grow at a CAGR of approximately 8.74% from 2023 to 2029.

The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:

  • Low-effectiveness of Non-pharmacological PE Treatment
  • Wide Accessibility of OTC Drugs and & General Off-label Drugs for PE
  • High Prevalence of Premature Ejaculation

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the global premature ejaculation therapeutics market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Company Profiles

  • Plethora Solutions
    • Business Overview
    • Product Offerings
  • Absorption Pharmaceuticals
  • Pfizer
  • Eli Lilly and Company
  • GSK plc
  • Bayer AG

Other Prominent Vendors

  • MidasCare
    • Business Overview
    • Product Offerings
  • Pound International
  • Momentum Management
  • Reckitt Benckiser Group
  • Recordati
  • Royalty Pharma
  • Shibari
  • The Menarini Group
  • Johnson & Johnson
  • Futura Medical
  • Niksan Pharmaceuticals
  • Amneal Pharmaceuticals

Segmentation by Drug Class

  • Selective Serotonin Re-uptake Inhibitors (SSRIs)
  • Phosphodiesterase type 5 (PDE5) Inhibitors
  • Anesthetic Agents
  • Others

Segmentation by Route of Administration

  • Oral Therapeutics
  • Topical Therapeutics

Segmentation by Age Group

  • Below 45 Years
  • Above 45 Years

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
  • APAC
    • Japan
    • India
    • China
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

CHAPTER – 1: PE Therapeutics Market Overview

  • Executive Summary
  • Key Findings

CHAPTER – 2: PE Therapeutics Market

  • GLOBAL: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)

CHAPTER – 3: PE Therapeutics Market Segmentation Data

  • GLOBAL: Projected Revenue by Drug Class (2023-2029; $Millions)
  • SSRIs
  • PDE-5 Inhibitors
  • Anesthetic Agents
  • Others
  • GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Millions)
  • Oral Therapeutics
  • Topical Therapeutics
  • GLOBAL: Projected Revenue by Age Group (2023-2029; $Millions)
  • Below 45 years
  • Above 45 years

CHAPTER – 4: Key Regions Overview

  • North America: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
  • Projected Revenue of PE Therapeutics Market in US
  • Projected Revenue of PE Therapeutics Market in Canada
  • Europe: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
  • Projected Revenue of PE Therapeutics Market in Germany
  • Projected Revenue of PE Therapeutics Market in UK
  • Projected Revenue of PE Therapeutics Market in France
  • Projected Revenue of PE Therapeutics Market in Italy
  • Projected Revenue of PE Therapeutics Market in Spain
  • APAC: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
  • Projected Revenue of PE Therapeutics Market in Japan
  • Projected Revenue of PE Therapeutics Market in India
  • Projected Revenue of PE Therapeutics Market in China
  • Latin America: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
  • Projected Revenue of PE Therapeutics Market in Brazil
  • Projected Revenue of PE Therapeutics Market in Mexico
  • Projected Revenue of PE Therapeutics Market in Argentina
  • Middle East & Africa: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
  • Projected Revenue of PE Therapeutics Market in Turkey
  • Projected Revenue of PE Therapeutics Market in Saudi Arabia
  • Projected Revenue of PE Therapeutics Market in South Africa

CHAPTER – 5: PE Therapeutics Market Prospects & Opportunities

  • PE Therapeutics Market Opportunities & Trends
  • PE Therapeutics Market Drivers
  • PE Therapeutics Market Constraints

CHAPTER – 6: PE Therapeutics Industry Overview

  • PE Therapeutics Market - Competitive Landscape
  • PE Therapeutics Market – Key Vendor Profiles
  • PE Therapeutics Market – Other Prominent Vendors
  • PE Therapeutics Market - Key Strategic Recommendations

CHAPTER – 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

List of Exhibits

  • Exhibit 1: Projected Revenues of PE Therapeutics in Global (2023-2029; $ Mn)
  • Exhibit 2: Projected Revenue of PE Therapeutics by SSRIs (2023-2029; $ Mn)
  • Exhibit 3: Projected Revenue of PE Therapeutics by PDE-5 Inhibitors ($ Mn)
  • Exhibit 4: Projected Revenues of PE Therapeutics by Anesthetic Agents (2023-2029; $ Mn)
  • Exhibit 5: Projected Revenues of PE Therapeutics by Others (2023-2029; $ Mn)
  • Exhibit 6: Projected Revenues of PE Therapeutics by Oral (2023-2029; $ Mn)
  • Exhibit 7: Projected Revenues of PE Therapeutics by Topical (2023-2029; $ Mn)
  • Exhibit 8: Projected Revenues of PE Therapeutics by Below 45 years (2023-2029; $ Mn)
  • Exhibit 9: Projected Revenues of PE Therapeutics by Above 45 years (2023-2029; $ Mn)
  • Exhibit 10: Projected Revenues of PE Therapeutics in North America (2023-2029; $ Mn)
  • Exhibit 11: Projected Revenues of PE Therapeutics in US (2023-2029; $ Mn)
  • Exhibit 12: Projected Revenues of PE Therapeutics in Canada (2023-2029; $ Mn)
  • Exhibit 13: Projected Revenues of PE Therapeutics in Europe (2023-2029; $ Mn)
  • Exhibit 14: Projected Revenues of PE Therapeutics in Germany (2023-2029; $ Mn)
  • Exhibit 15: Projected Revenues of PE Therapeutics in France (2023-2029; $ Mn)
  • Exhibit 16: Projected Revenues of PE Therapeutics in UK (2023-2029; $ Mn)
  • Exhibit 17: Projected Revenues of PE Therapeutics in Italy (2023-2029; $ Mn)
  • Exhibit 18: Projected Revenues of PE Therapeutics in Spain (2023-2029; $ Mn)
  • Exhibit 19: Projected Revenues of PE Therapeutics in APAC (2023-2029; $ Mn)
  • Exhibit 20: Projected Revenues of PE Therapeutics in Japan (2023-2029; $ Mn)
  • Exhibit 21: Projected Revenues of PE Therapeutics in China (2023-2029; $ Mn)
  • Exhibit 22: Projected Revenues of PE Therapeutics in India (2023-2029; $ Mn)
  • Exhibit 23: Projected Revenues of PE Therapeutics in Latin America (2023-2029; $ Mn)
  • Exhibit 24: Projected Revenues of PE Therapeutics in Brazil (2023-2029; $ Mn)
  • Exhibit 25: Projected Revenues of PE Therapeutics in Mexico (2023-2029; $ Mn)
  • Exhibit 26: Projected Revenues of PE Therapeutics in Argentina (2023-2029; $ Mn)
  • Exhibit 27: Projected Revenues of PE Therapeutics in MEA (2023-2029; $ Mn)
  • Exhibit 28: Projected Revenues of PE Therapeutics in Turkey (2023-2029; $ Mn)
  • Exhibit 29: Projected Revenues of PE Therapeutics in Saudi Arabia (2023-2029; $ Mn)
  • Exhibit 30: Projected Revenues of PE Therapeutics in South Africa (2023-2029; $ Mn)

List of Tables

  • Table 1: Key Market Trends in PE Therapeutics Market
  • Table 2: Key Market Enablers in PE Therapeutics Market
  • Table 3: Key Market Constraints in PE Therapeutics Market
  • Table 4: Strategic Recommendations in PE Therapeutics Market

Select a license type that suits your business needs

single-user Single User Licence
$2500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$2999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$3999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date